Tiny Semaglutide Implant Could Sustain Weight Loss Long-Term
Vivani Medical is developing a subcutaneous implant delivering semaglutide continuously, aiming to help patients maintain GLP-1-driven weight loss.
Vivani Medical is betting that a miniature implant loaded with semaglutide — the active ingredient powering Novo Nordisk's blockbuster obesity injection Wegovy and its diabetes counterpart Ozempic — could solve one of the biggest challenges in weight-loss medicine: keeping the pounds off after treatment begins.
The device is designed to deliver semaglutide continuously beneath the skin, potentially removing the burden of weekly injections that patients currently face with existing GLP-1 receptor agonist therapies. Adherence has long been identified as a critical barrier to sustained outcomes in obesity treatment, and a long-acting implant approach could address that gap directly.
Read more Apple Sues OpenAI for Trade Secret Theft, Sparking Tech Backlash →
The development comes as the GLP-1 drug market has exploded in recent years, with Wegovy and Ozempic becoming two of the most talked-about pharmaceuticals globally. Vivani's implant strategy represents a next-generation bet — moving beyond injectable pens toward embedded, hands-free drug delivery that could extend therapeutic effect over a longer horizon without repeated dosing.
While Vivani's implant is still in development, the concept reflects a broader industry push to capture patients who struggle with consistency or access in the current GLP-1 landscape. If successful, such a device could reshape how clinicians approach long-term obesity management, shifting the model from ongoing prescriptions to periodic implant replacements.
Continue reading at US Top News and Analysis.
